Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Caplin Point Laboratories reported strong full-year FY26 results with consolidated revenue from operations of ₹2,187 Crores, up 12.9% YoY from ₹1,937 Crores. Net profit after tax (PAT) grew 20.1% to ₹650 Crores versus ₹541 Crores in the prior year. The company declared an interim dividend of ₹4 per share (200% on face value ₹2). US market revenue stood at ₹471 Crores, delivering 28.7% YoY growth. EBITDA margin showed expansion to approximately 36.7% from 34.9% in FY25. The auditor, Brahmayya & Co, issued an unmodified (clean) opinion on both standalone and consolidated financial statements with no going concern issues. Free cash reserves stood at ₹1,471 Crores with liquid assets of ₹2,726 Crores.
Strong financial performance with 20% PAT growth and margin expansion signals operational efficiency improvements. The clean audit opinion and robust cash position are positive indicators for shareholders.